Increased expression of tumor-associated trypsin inhibitor, TATI, in prostate cancer and in androgen-independent 22Rv1 cells
(2007) In European Urology 52(6). p.1670-1681- Abstract
- Objectives: Tumor-associated-trypsin inhibitor (TATI) is frequently coexpressed with trypsinogen in tumors. Recently, we found expression of trypsinogens in prostate cancer. We have now studied whether TATI is also expressed in prostate cancer and if TATI expression is associated with Gleason grade, proliferation, and neuroendocrine differentiation. Methods: Expression of TATI and prostate-specific antigen (PSA) was studied by immunohistochemistryand in situ hybridization, and that of chromogranin A (CgA) and Ki-67 by immunohistochemistry. Immunofluorometric assays were used to quantify TATI and PSA in serum from prostate cancer patients and in medium of 22Rv1 prostate cancer cells. Results: TATI expression was weak in benign prostatic... (More)
- Objectives: Tumor-associated-trypsin inhibitor (TATI) is frequently coexpressed with trypsinogen in tumors. Recently, we found expression of trypsinogens in prostate cancer. We have now studied whether TATI is also expressed in prostate cancer and if TATI expression is associated with Gleason grade, proliferation, and neuroendocrine differentiation. Methods: Expression of TATI and prostate-specific antigen (PSA) was studied by immunohistochemistryand in situ hybridization, and that of chromogranin A (CgA) and Ki-67 by immunohistochemistry. Immunofluorometric assays were used to quantify TATI and PSA in serum from prostate cancer patients and in medium of 22Rv1 prostate cancer cells. Results: TATI expression was weak in benign prostatic epithelium and moderate to strong in prostate cancer and high-grade prostatic intraepithelial neoplasia. There was no correlation between TATI and Ki-67 immunostaining in a tissue microarray of 115 prostate cancer cores, but strong expression of TATI was associated with higher Gleason grade (p = 0.002) and CgA immunostaining intensity (p = 0.012). Serum TATI was elevated in 44% (29 of 66) of patients with prostate cancer, and the levels correlated with serum PSA (p < 0.0001, r = 0.306). DU145, PC-3, LNCaP, and 22Rv1 cells contained TATI mRNA as determined by RT-PCR, but only 22Rv1 cells produced detectable TATI protein. The synthetic androgen R1881 decreased secretion of TATI from 22Rv1 cells. Conclusions: We demonstrate for the first time that TATI is expressed in the benign and malignant prostate. Increased TATI protein expression is found in high-grade tumors and in 22Rv1 cells in which it is regulated by androgens. (c) 2007 European Association of Urology. Published by Elsevier B.V. All rights reserved. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/966319
- author
- Paju, Annukka ; Hotakainen, Kristina ; Cao, Yue LU ; Laurila, Timo ; Gadaleanu, Virgil ; Hemminki, Akseli ; Stenman, Ulf-Hakan and Bjartell, Anders LU
- organization
- publishing date
- 2007
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- protease inhibitor, 22RV1 cells, Kallikreins, immunohistochemistry, in situ hybridization
- in
- European Urology
- volume
- 52
- issue
- 6
- pages
- 1670 - 1681
- publisher
- Elsevier
- external identifiers
-
- wos:000251409600021
- scopus:35748961384
- ISSN
- 1873-7560
- DOI
- 10.1016/j.eururo.2007.01.096
- language
- English
- LU publication?
- yes
- id
- a71a8e10-7c84-41df-83f9-0878336d4e31 (old id 966319)
- date added to LUP
- 2016-04-01 17:02:48
- date last changed
- 2022-02-20 18:15:44
@article{a71a8e10-7c84-41df-83f9-0878336d4e31,
abstract = {{Objectives: Tumor-associated-trypsin inhibitor (TATI) is frequently coexpressed with trypsinogen in tumors. Recently, we found expression of trypsinogens in prostate cancer. We have now studied whether TATI is also expressed in prostate cancer and if TATI expression is associated with Gleason grade, proliferation, and neuroendocrine differentiation. Methods: Expression of TATI and prostate-specific antigen (PSA) was studied by immunohistochemistryand in situ hybridization, and that of chromogranin A (CgA) and Ki-67 by immunohistochemistry. Immunofluorometric assays were used to quantify TATI and PSA in serum from prostate cancer patients and in medium of 22Rv1 prostate cancer cells. Results: TATI expression was weak in benign prostatic epithelium and moderate to strong in prostate cancer and high-grade prostatic intraepithelial neoplasia. There was no correlation between TATI and Ki-67 immunostaining in a tissue microarray of 115 prostate cancer cores, but strong expression of TATI was associated with higher Gleason grade (p = 0.002) and CgA immunostaining intensity (p = 0.012). Serum TATI was elevated in 44% (29 of 66) of patients with prostate cancer, and the levels correlated with serum PSA (p < 0.0001, r = 0.306). DU145, PC-3, LNCaP, and 22Rv1 cells contained TATI mRNA as determined by RT-PCR, but only 22Rv1 cells produced detectable TATI protein. The synthetic androgen R1881 decreased secretion of TATI from 22Rv1 cells. Conclusions: We demonstrate for the first time that TATI is expressed in the benign and malignant prostate. Increased TATI protein expression is found in high-grade tumors and in 22Rv1 cells in which it is regulated by androgens. (c) 2007 European Association of Urology. Published by Elsevier B.V. All rights reserved.}},
author = {{Paju, Annukka and Hotakainen, Kristina and Cao, Yue and Laurila, Timo and Gadaleanu, Virgil and Hemminki, Akseli and Stenman, Ulf-Hakan and Bjartell, Anders}},
issn = {{1873-7560}},
keywords = {{protease inhibitor; 22RV1 cells; Kallikreins; immunohistochemistry; in situ hybridization}},
language = {{eng}},
number = {{6}},
pages = {{1670--1681}},
publisher = {{Elsevier}},
series = {{European Urology}},
title = {{Increased expression of tumor-associated trypsin inhibitor, TATI, in prostate cancer and in androgen-independent 22Rv1 cells}},
url = {{http://dx.doi.org/10.1016/j.eururo.2007.01.096}},
doi = {{10.1016/j.eururo.2007.01.096}},
volume = {{52}},
year = {{2007}},
}